drugset
drugset / Trial / NCT02211157

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

NCT02211157 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess safety, pharmacokinetics and pharmacodynamics of BIRB 796 BS in escalating multiple doses with and without a 64 g fat breakfast at the 50 mg dose level

Timeline

Start
2000-03
Primary completion
2000-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBR 796 BS Unknown 20 mg Oral
Subject BIBR 796 BS Unknown 30 mg Oral
Subject BIBR 796 BS Unknown 50 mg Oral
Subject BIBR 796 BS Unknown 150 mg Oral
Subject BIBR 796 BS Unknown 300 mg Oral
Subject BIBR 796 BS Unknown 600 mg Oral

Indications

No indication recorded.